Abstract: The present invention further relates to using vaccinia virus complement control protein (VCP), factor H and/or a complement control protein (CCP)-containing protein as modulator of the entry and/or replication of pathogen(s), wherein the pathogen is a virus or bacteria. The present invention further relates to a method of prevention and/or treatment of influenza A virus (IAV) infection in a subject of need thereof and to a method of modulation of the entry and/or replication of pathogen(s) in a subject of need thereof.

Abstract: The present invention further relates to using vaccinia virus complement control protein (VCP), factor H and/or a complement control protein (CCP)-containing protein as modulator of the entry and/or replication of pathogen(s), wherein the pathogen is a virus or bacteria. The present invention further relates to a method of prevention and/or treatment of influenza A virus (IAV) infection in a subject of need thereof and to a method of modulation of the entry and/or replication of pathogen(s) in a subject of need thereof.

Abstract: A system receives discovery rule inputs that include addresses, verifies one or more device identifiers for one or more addresses, obtains device information from each verified device associated with the one or more verified device identifiers, determines whether each verified device is a discovered device based on the device information, and automatically adds each verified device as a discovered device to a management system without human intervention when it is determined that the verified device is discovered. The system further creates device configuration information, creates an identifier and password, provides device configuration information, the identifier, and the password, to each of the discovered devices based on the NETCONF or the Device Management Interface standards, waits for a connection from the discovered devices, imports device configuration information from the discovered devices when the connection has been established, and indicates that the discovered devices are managed devices.

Abstract: The present invention provides the use of formulation with surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state and increased apoptosis. Accordingly the utility of the invention can be extended in human subjects in resolution of eosinophilic inflammations in related diseases and disorders like neuromuscular and respiratory diseases with eosinophilia other than airway-hyperresponsiveness, allergy and asthma, hypereosinophilic leukemias, hypereosinophilc syndromes (rare hematological diseases), skin diseases like eosinophilia-Myalgia syndrome, eosinophilic fascitis, capillary leak syndromes (IL-2), Churg-Strauss syndrome, toxic oil syndrome, parasitosis, etc., where a large number of stimulated eosinophils accumulate and release a series of growth factors, cytokines, chemokines, bioactive lipid mediators, toxic oxygen metabolites.

Abstract: A system receives discovery rule inputs that include addresses, verifies one or more device identifiers for one or more addresses, obtains device information from each verified device associated with the one or more verified device identifiers, determines whether each verified device is a discovered device based on the device information, and automatically adds each verified device as a discovered device to a management system without human intervention when it is determined that the verified device is discovered. The system further creates device configuration information, creates an identifier and password, provides device configuration information, the identifier, and the password, to each of the discovered devices based on the NETCONF or the Device Management Interface standards, waits for a connection from the discovered devices, imports device configuration information from the discovered devices when the connection has been established, and indicates that the discovered devices are managed devices.

Abstract: A device initializes a total time estimate for a multi-phased and multi-threaded process, determines task information for a currently executing phase of the process, and determines time information for the currently executing phase of the process. The device also calculates an updated total time estimate for the process based on the task information and the time information for the currently executing phase of the process, and displays the updated total time estimate to a user associated with the device.

Abstract: The present invention provides the use of formulation with surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state and increased apoptosis. Accordingly the utility of the invention can be extended in human subjects in resolution of eosinophilic inflammations in related diseases and disorders like neuromuscular and respiratory diseases with eosinophilia other than airway-hyperresponsiveness, allergy and asthma, hypereosinophilic leukemias, hypereosinophilc syndromes (rare hematological diseases), skin diseases like eosinophilia-Myalgia syndrome, eosinophilic fascitis, capillary leak syndromes (IL-2), Churg-Strauss syndrome, toxic oil syndrome, parasitosis, etc., where a large number of stimulated eosinophils accumulate and release a series of growth factors, cytokines, chemokines, bioactive lipid mediators, toxic oxygen metabolites.